Pluristem Therapeutics, Inc.
(NASDAQ : PSTI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.29%300.261.4%$596.56m
AMGNAmgen, Inc.
0.15%233.771.3%$511.86m
GILDGilead Sciences, Inc.
1.74%67.081.0%$364.16m
REGNRegeneron Pharmaceuticals, Inc.
1.06%372.262.6%$296.10m
VRTXVertex Pharmaceuticals, Inc.
0.08%223.251.9%$267.50m
ILMNIllumina, Inc.
2.08%326.473.5%$239.80m
ALXNAlexion Pharmaceuticals, Inc.
6.02%113.892.0%$195.68m
ARWRArrowhead Pharmaceuticals, Inc.
2.66%67.2712.0%$195.66m
EXASEXACT Sciences Corp.
3.15%86.2424.0%$182.79m
CLVSClovis Oncology, Inc.
8.47%9.6114.7%$181.81m
SRPTSarepta Therapeutics, Inc.
-0.46%109.4614.6%$145.45m
AAgilent Technologies, Inc.
0.88%82.251.6%$143.48m
NBIXNeurocrine Biosciences, Inc.
0.28%116.815.0%$128.05m
BMRNBioMarin Pharmaceutical, Inc.
-0.20%79.924.3%$126.79m
SGENSeattle Genetics, Inc.
0.29%117.506.1%$126.10m

Company Profile

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.